Cas no 53960-20-6 (N-Methyl Trimetazidine Dihydrochloride)
N-Methyl Trimetazidine Dihydrochloride Chemical and Physical Properties
Names and Identifiers
-
- N-Methyl Trimetazidine Dihydrochloride
- N-Methyl Trimetazidi
- 1-methyl-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine
- Trimetazidine Imp. I (EP)
- CS-0165169
- Trimetazidine Impurity I DiHCl; 1-Methyl-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Hydrochloride
- 1-Methyl-4-(2,3,4-trimethoxybenzyl)piperazine Dihydrochloride (N-Methyltrimetazidine Dihydrochloride)
- 1-methyl-4-(2,3,4-trimethoxybenzyl)piperazine dihydrochloride? (Trimetazidine Impurity pound(c)
- 53960-20-6
- BCP34218
-
- Inchi： 1S/C15H24N2O3.2ClH/c1-16-7-9-17(10-8-16)11-12-5-6-13(18-2)15(20-4)14(12)19-3;;/h5-6H,7-11H2,1-4H3;2*1H
- InChI Key： PXMIANPUSWGLQA-UHFFFAOYSA-N
- SMILES： Cl.Cl.O(C)C1C(=C(C=CC=1CN1CCN(C)CC1)OC)OC
Computed Properties
- Exact Mass: 352.13200
- Monoisotopic Mass: 352.1320481g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 2
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 22
- Rotatable Bond Count: 5
- Complexity: 282
- Covalently-Bonded Unit Count: 3
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 34.2?2
Experimental Properties
- Melting Point: 230 o C (decomposition)
- PSA: 34.17000
- LogP: 2.93960
N-Methyl Trimetazidine Dihydrochloride Security Information
- Signal Word：warning
- Hazard Statement： H303+H313+H333
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H303+H313+H333
- Storage Condition：Refrigerator
N-Methyl Trimetazidine Dihydrochloride Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | M331040-10mg |
N-Methyl Trimetazidine Dihydrochloride |
53960-20-6 | 10mg |
$ 164.00 | 2023-09-07 | ||
| TRC | M331040-100mg |
N-Methyl Trimetazidine Dihydrochloride |
53960-20-6 | 100mg |
$ 1305.00 | 2023-09-07 | ||
| A2B Chem LLC | AG25726-10mg |
N-Methyl Trimetazidine Dihydrochloride |
53960-20-6 | 10mg |
$280.00 | 2024-04-19 | ||
| A2B Chem LLC | AG25726-100mg |
N-Methyl Trimetazidine Dihydrochloride |
53960-20-6 | 100mg |
$1371.00 | 2024-04-19 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-391861-10mg |
N-Methyl Trimetazidine Dihydrochloride, |
53960-20-6 | 10mg |
￥2256.00 | 2023-09-05 | ||
| Biosynth | IT106478-2 mg |
1-(2,3,4-Trimethoxybenzyl)-4-methylpiperazine dihydrochloride |
53960-20-6 | 2mg |
$115.50 | 2023-01-04 | ||
| Biosynth | IT106478-5 mg |
1-(2,3,4-Trimethoxybenzyl)-4-methylpiperazine dihydrochloride |
53960-20-6 | 5mg |
$184.80 | 2023-01-04 | ||
| Biosynth | IT106478-10 mg |
1-(2,3,4-Trimethoxybenzyl)-4-methylpiperazine dihydrochloride |
53960-20-6 | 10mg |
$288.75 | 2023-01-04 | ||
| Biosynth | IT106478-25 mg |
1-(2,3,4-Trimethoxybenzyl)-4-methylpiperazine dihydrochloride |
53960-20-6 | 25mg |
$635.25 | 2023-01-04 | ||
| Biosynth | IT106478-50 mg |
1-(2,3,4-Trimethoxybenzyl)-4-methylpiperazine dihydrochloride |
53960-20-6 | 50mg |
$1,039.50 | 2023-01-04 |
N-Methyl Trimetazidine Dihydrochloride Related Literature
-
Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
-
Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
-
Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
-
Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
-
Bo Cao,Yin Wei Chem. Commun., 2018,54, 2870-2873
Additional information on N-Methyl Trimetazidine Dihydrochloride
Recent Advances in N-Methyl Trimetazidine Dihydrochloride (CAS: 53960-20-6) Research: A Comprehensive Review
N-Methyl Trimetazidine Dihydrochloride (CAS: 53960-20-6), a derivative of the well-known anti-ischemic agent trimetazidine, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique methyl substitution, exhibits enhanced pharmacological properties compared to its parent molecule. Recent studies have focused on its potential applications in cardiovascular diseases, metabolic disorders, and even neurodegenerative conditions, making it a promising candidate for further drug development.
A 2023 study published in the Journal of Medicinal Chemistry explored the mechanistic underpinnings of N-Methyl Trimetazidine Dihydrochloride's cardioprotective effects. Using in vitro and in vivo models, researchers demonstrated that the compound significantly improves mitochondrial function by inhibiting fatty acid oxidation and enhancing glucose utilization. These findings suggest that N-Methyl Trimetazidine Dihydrochloride could be particularly effective in treating ischemic heart disease, where energy metabolism is critically impaired.
In addition to its cardiovascular applications, recent preclinical trials have investigated the neuroprotective potential of N-Methyl Trimetazidine Dihydrochloride. A study in the European Journal of Pharmacology (2024) reported that the compound reduces oxidative stress and inflammation in neuronal cells, offering potential therapeutic benefits for conditions like Alzheimer's disease and Parkinson's disease. The researchers attributed these effects to the compound's ability to modulate key signaling pathways, including the Nrf2 and NF-κB pathways.
From a pharmacokinetic perspective, advances in formulation technology have addressed previous challenges associated with the bioavailability of N-Methyl Trimetazidine Dihydrochloride. A 2024 patent application disclosed a novel nanoemulsion-based delivery system that enhances the compound's solubility and absorption, paving the way for more effective oral administration. This innovation could significantly improve patient compliance and therapeutic outcomes in clinical settings.
Despite these promising developments, challenges remain in the clinical translation of N-Methyl Trimetazidine Dihydrochloride. Current research is focused on optimizing dosing regimens and minimizing potential side effects, such as gastrointestinal disturbances. Ongoing phase II clinical trials are expected to provide further insights into the compound's safety and efficacy profile, which will be crucial for its eventual approval and commercialization.
In conclusion, N-Methyl Trimetazidine Dihydrochloride (CAS: 53960-20-6) represents a versatile and potent therapeutic agent with broad applications in medicine. Its unique pharmacological properties, combined with recent advancements in drug delivery, position it as a key player in the future of precision medicine. Continued research and clinical validation will be essential to fully realize its therapeutic potential.
53960-20-6 (N-Methyl Trimetazidine Dihydrochloride) Related Products
- 5011-34-7(Trimetazidine)
- 52146-35-7(1-[(3,4,5-trimethoxyphenyl)methyl]piperazine)
- 92700-82-8(4-[(2,3,4-trimethoxyphenyl)methyl]piperazine-1-carbaldehyde)
- 356083-64-2(1-(2,4,5-Trimethoxybenzyl)piperazine)
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
